DrugPatentWatch Archives

You are currently viewing the 2010 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ORAVIG

Summary for Tradename: ORAVIG

Suppliers: see list1
patent expirations by year for

Pharmacology for Tradename: ORAVIG

Drug ClassAzole Antifungal

Clinical Trials for: ORAVIG

Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients
Status: Completed Condition: HIV Infections

Uptake of the Antifungal Miconazole and Effect on Estrogen Metabolizing Enzymes in Humans
Status: Completed Condition: Healthy

Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches
Status: Enrolling by invitation Condition: Oral Candidiasis; Denture Stomatitis

Clinical Trial of Hydroquinone Versus Miconazol in Melasma
Status: Recruiting Condition: Melasma

Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
Status: Completed Condition: Candidiasis, Oral

Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients
Status: Recruiting Condition: Otomycosis

Comparative Efficacy of Ovule vs Tablet
Status: Completed Condition: Clotrimazole; Ovulen; Vulvovaginal Candidiasis

Study to Evaluate the Clinical Outcome in High Risk Patients Who Received Empirical Antifungal Therapy
Status: Active, not recruiting Condition: Antifungal Therapy

Antifungal Use in Oncohematological Neutropenic Patients
Status: Completed Condition: Invader Fungal Infection

Antifungal Locks to Treat Fungal-Related Central Line Infections
Status: Recruiting Condition: Central Line Fungal Infections

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bioalliance Pharma
TABLET; BUCCAL022404Apr 16, 2010RXYes<disabled><disabled>
Bioalliance Pharma
TABLET; BUCCAL022404Apr 16, 2010RXYes6,916,485<disabled>Y<disabled>
Bioalliance Pharma
TABLET; BUCCAL022404Apr 16, 2010RXYes7,651,698<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology